Recently, as part of the Cancer Genome Atlas (TCGA) studies, enhancer activity has been mapped across nearly 9000 cancer patients combining RNA-seq and Hi-C data to characterize enhancer-gene interactions, and this effort identified a key enhancer of the immunomodulatory protein programmed death ligand 1 (PD-L1) (Chen et al., 2018). This evidence concerns the gene CD274 and cancer.